Viewing Study NCT03614858


Ignite Creation Date: 2025-12-25 @ 12:17 AM
Ignite Modification Date: 2026-02-24 @ 10:06 AM
Study NCT ID: NCT03614858
Status: RECRUITING
Last Update Posted: 2023-11-29
First Post: 2018-07-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module